BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

被引：3

作者：

Tartof, Sara Y. ^{[1
,2
]}

Frankland, Timothy B. ^{[3
]}

Puzniak, Laura ^{[4
]}

Slezak, Jeff M. ^{[1
]}

Hong, Vennis ^{[1
]}

Takhar, Harpreet ^{[1
]}

Ogun, Oluwaseye A. ^{[1
]}

Simmons, Sarah ^{[1
]}

Xie, Fagen ^{[1
]}

Zamparo, Joann ^{[4
]}

Ackerson, Bradley K. ^{[5
]}

Jodar, Luis ^{[4
]}

McLaughlin, John M. ^{[4
]}

机构：

[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 1000 S Los Robles,2nd Floor, Pasadena, CA 91101 USA

[2] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA

[3] Kaiser Permanente Hawaii Ctr Integrated Hlth Care, Honolulu, HI USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Southern Calif Permanente Med Grp, Harbor City, CA USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2023年 / 12卷 / 03期

关键词：

BNT162b2; booster; COVID-19; delta; effectiveness; Kaiser Permanente; omicron; pediatric; real-world; SARS-CoV-2; test-negative; United States; VACCINE;

D O I：

10.1093/jpids/piad005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after >= 3 months. A booster improved protection to 77% [53-88].

引用

页码：177 / 179

页数：3

共 50 条

[1] BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Mintzker, Yishai
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06): : 604 - 606
[2] Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel
Glatman-Freedman, Aharona
Hershkovitz, Yael
Dichtiar, Rita
Rosenberg, Alina
Keinan-Boker, Lital
Bromberg, Michal
EMERGING INFECTIOUS DISEASES, 2023, 29 (04) : 771 - 777
[3] More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Walter, Emmanuel B.
Talaat, Kawsar R.
Gurtman, Alejandra
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1191 - 1193
[4] Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Walter, E. B.
Talaat, K. R.
Sabharwal, C.
Gurtman, A.
Lockhart, S.
Paulsen, G. C.
Barnett, E. D.
Munoz, F. M.
Maldonado, Y.
Pahud, B. A.
Domachowske, J. B.
Simoes, E. A. F.
Sarwar, U. N.
Kitchin, N.
Cunliffe, L.
Rojo, P.
Kuchar, E.
Ramet, M.
Munjal, I
Perez, J. L.
Frenck, R. W., Jr.
Lagkadinou, E.
Swanson, K. A.
Ma, H.
Xu, X.
Koury, K.
Mather, S.
Belanger, T. J.
Cooper, D.
Tureci, O.
Dormitzer, P. R.
Jansen, K. U.
Gruber, W. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (01): : 35 - 46
[5] BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age REPLY
Walter, Emmanuel B.
Talaat, Kawsar R.
Gurtman, Alejandra
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06): : 606 - 606
[6] Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5-11 years of age in Brazil: A prospective test-negative design study
Rodrigues, Cristina de Oliveira
Spinardi, Julia
Rosa, Regis Goulart
Falavigna, Maicon
de Souza, Emanuel Maltempi
Manfio, Joselia Larger
Souza, Ana Paula de
de Araujo, Cintia Laura Pereira
Cohen, Mirian
Barbosa, Gynara Rezende Gonzalez do Valle
Silva, Fernanda Kelly Romeiro
Sganzerla, Daniel
da Silva, Mariana Motta Dias
Ferreira, Diogo
Kunkel, Nicolas Taciano
Camargo, Nathan Iori
Sarturi, Jean Carlos
Guilhem, Marcia Cristina
de Oliveira, Jaqueline Carvalho
Lopes, Caroline Cardoso
Widmar, Fernanda
Barufi, Leticia Killes
da Silva, Gabrielle Nunes
Gradia, Daniela Fiori
Brandalize, Ana Paula Carneiro
Royer, Carla Adriane
Luiz, Rafael Messias
Baura, Valter Antonio
Abreu, Hellen
Poitevin, Carolina Gracia
Kucharski, Gabriela Almeida
Pedrotti, Fernando
Valluri, Srinivas Rao
Srivastava, Amit
Juliao, Viviane Wal
Melone, Olga Chameh
Allen, Kristen E.
Kyaw, Moe H.
Castillo, Graciela del Carmen Morales
Mclaughlin, John
IMMUNOLOGY LETTERS, 2024, 269
[7] BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
Cohen-Stavi, Chandra J.
Magen, Ori
Barda, Noam
Yaron, Shlomit
Peretz, Alon
Netzer, Doron
Giaquinto, Carlo
Judd, Ali
Leibovici, Leonard
Hernan, Miguel A.
Lipsitch, Marc
Reis, Ben Y.
Balicer, Ran D.
Dagan, Noa
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03): : 227 - 236
[8] Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
Tan, Sharon H. X.
Cook, Alex R.
Heng, Derrick
Ong, Benjamin
Lye, David C.
Tan, Kelvin B.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06): : 525 - 532
[9] BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age
Tartof, Sara Y.
Frankland, Timothy B.
Puzniak, Laura
Slezak, Jeff M.
Ackerson, Bradley K.
Hong, Vennis
Stern, Julie
Zamparo, Joann M.
Chowdhry, Hina
Spence, Brigitte
Davis, Gregg S.
Jodar, Luis
Mclaughlin, John M.
JAMA NETWORK OPEN, 2024, 7 (12)
[10] Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
Mungmunpuntipantip, Rujittika
Wiwanitkit, Viroj
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022,

← 1 2 3 4 5 →